0000950170-24-009505.txt : 20240131
0000950170-24-009505.hdr.sgml : 20240131
20240131174505
ACCESSION NUMBER: 0000950170-24-009505
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240129
FILED AS OF DATE: 20240131
DATE AS OF CHANGE: 20240131
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kulkarni Samarth
CENTRAL INDEX KEY: 0001682019
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37923
FILM NUMBER: 24584163
MAIL ADDRESS:
STREET 1: C/O CRISPR THERAPEUTICS AG
STREET 2: 200 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CRISPR Therapeutics AG
CENTRAL INDEX KEY: 0001674416
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 473173478
STATE OF INCORPORATION: V8
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: BAARERSTRASSE 14
CITY: ZUG
STATE: V8
ZIP: CH-6300
BUSINESS PHONE: 6173154600
MAIL ADDRESS:
STREET 1: BAARERSTRASSE 14
CITY: ZUG
STATE: V8
ZIP: CH-6300
4
1
ownership.xml
4
X0508
4
2024-01-29
0001674416
CRISPR Therapeutics AG
CRSP
0001682019
Kulkarni Samarth
C/O CRISPR THERAPEUTICS
105 WEST FIRST STREET
BOSTON
MA
02127
true
true
false
false
Chief Executive Officer
true
Common Shares
2024-01-29
4
M
false
50000
19.12
A
237377
D
Common Shares
2024-01-29
4
S
false
49300.00
60.5031
D
188077
D
Common Shares
2024-01-29
4
S
false
700.00
61.0998
D
187377
D
Common Shares
200000
I
The Kulkarni 2023 GRAT
Stock Option (Right to Buy)
19.12
2024-01-29
4
M
false
50000
D
2027-12-01
Common Shares
50000
100000
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2023
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.04 to $61.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.04 to $61.155, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
This performance-based stock option was granted on December 1, 2017 with respect to 150,000 Common Shares and was subject to both time- and performance-based vesting. Performance-based stock options vested as to 112,500 options on December 1, 2020 and 37,500 options on December 1, 2021, based on the Company's performance over the applicable performance period, and subject to the terms and conditions of the agreement evidencing the award and the Company's 2016 Stock Option and Incentive Plan.
Not applicable.
/s/ Elizabeth Ryland Waldinger, attorney-in-fact
2024-01-31